PRODUCTION OF SOLUBLE HUMAN T CELL RECEPTOR CHAINS

描述：（改编自申请人摘要）T细胞恶性肿瘤 占所有淋巴瘤的15%，目前的治疗通常不会产生 显著的长期缓解。申请人提出治疗T细胞 通过诱导特异性细胞免疫反应来“拒绝”淋巴瘤， 某些增殖的T细胞癌症免疫疗法的圣杯是 鉴定可用于教导免疫的特异性肿瘤标志物 去除不需要的细胞群而留下其它细胞的系统 完整他们认为，T细胞受体应该作为一种肿瘤标志物， 尤其是T细胞淋巴瘤如果有足够数量的可溶性T细胞受体 那么通过接种疫苗治疗淋巴瘤可能是可行的。 然而，T细胞受体不是以可溶形式天然表达的。的 申请人提出通过生产重组可溶性 昆虫细胞中的T细胞受体链。在第一阶段，他们将测试 这种治疗方法在动物模型中的可行性。它们会跳动 自体专职抗原呈递细胞与重组小鼠T细胞 受体β链离体ant将处理的细胞转移到小鼠中， 用致瘤性T细胞系攻击。如果成功的话，他们将 II期人体T细胞受体研究和III期临床试验。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) T-cell malignancies account for 15% of all lymphomas and current treatments do not usually yield significant long-term remission. The applicants propose to treat T-cell lymphoma by inducing a specific cellular immune response to "reject" only the certain proliferating T-cells. The Holy Grail of cancer immunotherapy is the identification of specific tumor markers that can be used to teach the immune system to remove the undesired population of cells while leaving other cells intact. They believe that a T-cell receptor should act as a tumor marker for a particular T-cell lymphoma. If sufficient quantities of soluble T-cell receptor were available then treatment of lymphoma by vaccination might be feasible. However, T-cell receptors are not naturally expressed in soluble form. The applicants propose to solve this problem by producing recombinant soluble T-cell receptor chains in insect cells. In Phase I they will test the feasibility of this therapeutic approach in an animal model. They will pulse autologous professional antigen presenting cells with recombinant mouse T-cell receptor beta chain ex vivo ant transfer the treated cells into mice prior to challenge with a tumorigenic T-cell line. If successful, they will extend their studies to human T-cell receptors in Phase II and clinical trials in Phase III. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE